InnoCare Pharma Signs Lilly R&D, Upfronts Up To $100M, Milestones Up To $3.25B

InnoCare Pharma entered a research collaboration and license deal with Eli Lilly, with up to $100M in upfront/near-term payments and up to ~$3.25B in milestones, plus single-digit tiered royalties.Material DetailsContext by AI AnalystThis expands InnoCare’s partnering strategy to monetize its disco…